Andrew Ko

9PUBLICATIONS
72CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGlycoconjugatesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 14, 2026
A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.

|Feb 13, 2026
Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.

Xiaolin Zhu, Edwin A Alvarez, Sarah E Umetsu

|Feb 05, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.

Andrew H Ko, Joseph Chao, Marcus S Noel

|Mar 05, 2024
A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer.

Andrew H Ko, Andrew L Coveler, Benjamin L Schlechter

|Jan 05, 2024
Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer.

Maira Soto, Erin L Filbert, Hai Yang

Pageof 2

Frequent Collaborators

3 joint publications

Lawrence Fong

3 joint publications

Bridget P Keenan

2 joint publications

Frank J Hsu

2 joint publications

Erin L Filbert